With the approval of capmatinib, how would you approach a newly diagnosed metastatic NSCLC with MET Exon 14 skipping mutation?

Topics: Thoracic Malignancies • Medical Oncology • NCI-CCC Tumor Board Question • Ohio State University • MET+

Answer from: Medical Oncologist at Academic Institution

Somatic MET mutations leading to splicing-mediated loss of exon 14 and subsequent MET overexpression are an emerging therapeutic target present in 2-4% of lung adenocarcinomas (1, 2). MET tyrosine kinase inhibitor (TKI) treatment was associated with improved overall survival in a retrospective...

Comments

Medical Oncologist at University of Michigan Medical School
@Collin Blakely has clearly stated the relevant da...

Medical Oncologist at Florida Cancer Specialists and Research Institute
For patients who were placed on first line chemo i...

Medical Oncologist at Kaiser Permanente Northwest
I would wait for progression.

Medical Oncologist at Yuma Regional Medical Center Cancer Center
And, any thoughts about non-exon 14 skip mutations...

Related Questions